spacer
home > ict > spring 2020 > pushing ‘go’ again on clinical trials in a post-covid-19 world
PUBLICATIONS
International Clinical Trials

Pushing ‘Go’ Again on Clinical Trials in a Post-COVID-19 World



When the word ‘coronavirus’ entered the general consciousness in early 2020, little did we know the extent to which this new disease would essentially press pause on our daily lives. The true ramifications of lockdowns, social distancing, self-isolation, as well as hospital closures caused by the pandemic are as yet unknown, and will likely reverberate for a generation.

What we do know is across several weeks of firefighting to respond to the immediate situation, clinical trial sponsors have not yet got to thinking about what happens next. Clearly the current challenges are daunting. There’s a lot that needs to happen before we start thinking about patients travelling to sites again for their regular visits, but it’s worth starting to consider what happens when pharma companies do decide to press the ‘go’ button again.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the company

Illingworth Research Group is a provider of patient-centric clinical research solutions. This can be, but is not exclusive to, mobile research nursing, patient concierge, and medical photography. Services are operational in 45 countries and concentrate on taking the trial to the patient or making trial participation easier and more accessible to patients and their families. illingworthresearch.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

BRIM Biotechnology, Inc. Raises $20 Million in Series E Funding Round

Taipei, Taiwan, 1st December 2022 / Sciad Newswire / BRIM Biotechnology, Inc. ("BRIM," TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, announced today that it has raised $20 million in its Series E funding round. This demonstrates the heightened interest and growing demand for new treatments for Dry Eye Disease (DED). News of this latest funding round comes as BRIM prepares to initiate the Phase 3 clinical trial for its lead asset BRM421 for DED in the US.
More info >>

White Papers

Key to Outsourcing Method Development and Validation A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement